Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Williams

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2009
Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent mannerMoutih Rafei, Philippe M Campeau, Adriana Aguilar-Mahecha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2024
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLCMauricio Burotto, Zanete Zvirbule, Renzo Alvarez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2020
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib StudyJohn W Moroney, John Powderly, Christopher H Lieu, et al.
Retina (Philadelphia, Pa.)|April 9, 2026
Dexamethasone implant and aflibercept combination therapy versus aflibercept monotherapy for diabetic macular edema: A prospective, comparative trial (COED trial)Irene Park Kim, Christine Orndahl, Caroline Nyaiburi, et al.
Molecular Cancer|September 28, 2011
A MCP1 fusokine with CCR2-specific tumoricidal activityMoutih Rafei, Jiusheng Deng, Marie-Noëlle Boivin, et al.
Journal for Immunotherapy of Cancer|October 4, 2023
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunityPaul Koller, Natalia Baran, Karine Harutyunyan, et al.
Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2009
Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent mannerMoutih Rafei, Philippe M Campeau, Adriana Aguilar-Mahecha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2024
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLCMauricio Burotto, Zanete Zvirbule, Renzo Alvarez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2020
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib StudyJohn W Moroney, John Powderly, Christopher H Lieu, et al.
Retina (Philadelphia, Pa.)|April 9, 2026
Dexamethasone implant and aflibercept combination therapy versus aflibercept monotherapy for diabetic macular edema: A prospective, comparative trial (COED trial)Irene Park Kim, Christine Orndahl, Caroline Nyaiburi, et al.
Molecular Cancer|September 28, 2011
A MCP1 fusokine with CCR2-specific tumoricidal activityMoutih Rafei, Jiusheng Deng, Marie-Noëlle Boivin, et al.
Journal for Immunotherapy of Cancer|October 4, 2023
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunityPaul Koller, Natalia Baran, Karine Harutyunyan, et al.
Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Pageof 6